Fighting Hypoxia to Improve PDT

Pharmaceuticals

Noémie Thomas¹  Philippe Arnoux²  Ludivine Larue²  Céline Frochot²  Francis Baros²  Albert Moussaron²  Amina Ben-Mihoub³  Régis Vanderesse³  Samir Acherar³  Bauyrzhan Myrzakhmetov⁴ 

[1] Biologie, Signaux et Systèmes en Cancérologie et Neurosciences, CRAN, UMR 7039, Université de Lorraine, CNRS, 54000 Nancy, France;Laboratoire Réactions et Génie des Procédés (LRGP), UMR 7274, CNRS, Université de Lorraine, 54000 Nancy, France;Laboratoire de Chimie Physique Macromoléculaire (LCPM), UMR 7375, CNRS, Université de Lorraine, 54000 Nancy, France;M.Kh. Dulaty Taraz State University, 080012 Taraz, Kazakhstan;

关键词: pdt;    oxygen;    hypoxia;   

DOI  :  10.3390/ph12040163

来源: DOAJ

【 摘 要 】

Photodynamic therapy (PDT) has drawn great interest in recent years mainly due to its low side effects and few drug resistances. Nevertheless, one of the issues of PDT is the need for oxygen to induce a photodynamic effect. Tumours often have low oxygen concentrations, related to the abnormal structure of the microvessels leading to an ineffective blood distribution. Moreover, PDT consumes O₂. In order to improve the oxygenation of tumour or decrease hypoxia, different strategies are developed and are described in this review: 1) The use of O₂ vehicle; 2) the modification of the tumour microenvironment (TME); 3) combining other therapies with PDT; 4) hypoxia-independent PDT; 5) hypoxia-dependent PDT and 6) fractional PDT.

【 授权许可】

Unknown